Associated Papers
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.
Kuras M et al.
Cancers, 2025
Single-cell exome sequencing reveals polyclonal seeding and TRPS1 mutations in colon cancer metastasis.
Cai J et al.
Signal Transduction and Targeted Therapy, 2024
Clinical and genomic features of non-small cell lung cancer occurring in families.
Miyabe S et al.
Thoracic Cancer, 2023
An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report).
Panebianco M et al.
Current Oncology (toronto, Ont.), 2021
Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN® System Comprehensive Approach.
Roberto M et al.
Pharmaceuticals (basel, Switzerland), 2021
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D et al.
Hemasphere, 2020
The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico.
Martínez-Magaña JJ et al.
Frontiers in Pharmacology, 2020
Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry.
Minarik L et al.
Folia Biologica, 2020
Introducing the first whole genomes of nationals from the United Arab Emirates.
AlSafar HS et al.
Scientific Reports, 2019
Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer.
Yoshikawa T et al.
Journal of Cancer, 2019
Identification of novel compound heterozygous SPG7 mutations-related hereditary spastic paraplegia in a Chinese family: a case report.
Zhang X et al.
Bmc Neurology, 2018
Assessment of coding region variants in Kuwaiti population: implications for medical genetics and population genomics.
John SE et al.
Scientific Reports, 2018
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2018
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
Li Z et al.
Oncotarget, 2016
Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
Matsusaka S et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK et al.
Nature Communications, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Saif MW et al.
Mayo Clinic Proceedings, 2014
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.
Duldulao MP et al.
Cancer, 2013
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.
Jennings BA et al.
Plos One, 2013
Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies.
Ghosh S et al.
Plos One, 2012
Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.
Ghosh S et al.
Cancer Biology & Therapy, 2011
Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays.
Gusella M et al.
Genetic Testing and Molecular Biomarkers, 2011
VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea.
Formica V et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2011
Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Afzal S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Tsunoda A et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2011
Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.
Schwarzenbach H
The Epma Journal, 2010
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Shahrokni A et al.
Clinical Colorectal Cancer, 2009
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2009
Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
Journal of Gastroenterology and Hepatology, 2009
Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Shahrokni A et al.
Jop : Journal of the Pancreas, 2009
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Goekkurt E et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2009
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
Ichikawa W et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer.
Kitajima M et al.
Oncology Reports, 2006
Genetic factors influencing pyrimidine-antagonist chemotherapy.
Maring JG et al.
The Pharmacogenomics Journal, 2005
Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families.
Suchi M et al.
American Journal of Human Genetics, 1997